Older patients often face more complex health issues and higher risks of adverse effects from treatments; hence, a study was conducted to assess the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in reducing hospitalizations in patients aged 80 and above.
 
**Key findings:**
- Reduced risk of all-cause death [HR: 0.58] and HFH (HR: 0.69) 
-No signiﬁcant interactions between age, diabetes, body mass index, left ventricular ejection fraction, clinical frailty scale, geriatric nutritional risk index
-No increase in safety composite outcomes at any strata

It can be concluded that SGLT2 inhibitors are both safe and effective for elderly patients with heart failure, improving heart function and reducing hospital admissions due to heart failure-related complications. This is particularly important as the elderly population is more susceptible and treatments that provide benefits without significant risks are crucial.

Source: BMJ Journals| [Read Full Story] (https://heart.bmj.com/content/early/2025/01/20/heartjnl-2024-324988?rss=1)